Our global life sciences company brings diagnostic testing & drug development together.
Hepatitis A Virus (HAV) Antibody, Total; Hepatitis B Surface Antibody (anti-HBs); and Hepatitis B c Antibody (anti-HBc), Total
This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.
1 - 2 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Serum or EDTA plasma
1 mL (Note: This volume does not allow for repeat testing.)
Gel-barrier tube, red-top tube, lavender-top (EDTA) tube, plastic transport tube
If tube other than a gel-barrier tube is used, transfer separated serum/plasma to a labelled plastic transport tube. Do not freeze gel-barrier tube (pour off serum first).
Heat-inactivated specimens; cord blood; cadaveric specimens; or body fluids other than serum or EDTA plasma; gross hemolysis; excessive lipemia; improper labeling
To access patients for immunity to Hepatitis A Virus (HAV) and Hepatitis B Virus (HBV). Detectable total anti-HAV antibody indicates immunity to HAV infection. Although usually not sensitive enough to detect the low level of protective antibody after vaccination, anti-HAV tests also might be positive after hepatitis A vaccination. The detection of anti-HBs antibodies in the absence of anti-HBc antibodies indicates immunity to HBV infection due to vaccination. The detection of both anti-HBs and anti-HBc antibodies indicates immunity due to natural infection.
The assays in this panel have not been FDA cleared or approved for the screening of blood or plasma donors. Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients, coed blood, or patients less than 2 years of age.
Immunochemiluminometric assay (ICMA)
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf